Evidence map›Paper›PMID 31134829›Full record

Trial reportCell transplantation2019

Anti-Platelet Therapy in Mild Cerebral Infarction Patients on the Basis of CYP2C19 Metabolizer Status.

Hu Lan, Tang Ying, Sheng Xi-Hua, Li Yi

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Pharmacogenetics of P2YPharmacotherapy · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hu Lan1 Department of Neurology, First People's Hospital of Wujiang District, Suzhou City, Jiangsu Province, P.R. China.ORCID 0000-0001-8962-7149
Tang Ying2 Department of Central Laboratory, First People's Hospital of Wujiang District, Suzhou City, Jiangsu Province, P.R. China.
Sheng Xi-Hua1 Department of Neurology, First People's Hospital of Wujiang District, Suzhou City, Jiangsu Province, P.R. China.
Li Yi3 Department of Neurosurgery, Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the effects of CYP2C19 metabolizer status on the clinical therapeutic efficacy of cerebral infarction. Patients with cerebral infarction (

Indexed as

AgedCerebral InfarctionCytochrome P-450 CYP2C19Endpoint DeterminationFemaleGenotypeHumansMalePhenotypePlatelet Aggregation InhibitorsPolymorphism, GeneticTreatment OutcomeCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation Inhibitorsclinical efficacyclopidogrelCYP2C19metabolizer statusrecurrence rate

Identifiers

PMID31134829
PMCPMC6728712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.